Zydus Wellness Ltd
Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.(Source : 202003 Annual Report Page No: 83)
- Market Cap ₹ 10,693 Cr.
- Current Price ₹ 1,680
- High / Low ₹ 2,484 / 1,480
- Stock P/E 33.4
- Book Value ₹ 863
- Dividend Yield 0.30 %
- ROCE 5.33 %
- ROE 5.32 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Tax rate seems low
- Company has a low return on equity of 6.08% over last 3 years.
- Dividend payout has been low at 10.8% of profits over last 3 years
- Debtor days have increased from 34.6 to 44.4 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: FMCG Industry: Food - Processing - Indian
Part of BSE 500 BSE SmallCap BSE 400 MidSmallCap Index BSE Fast Moving Consumer Goods Nifty Microcap 250
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
388 | 404 | 431 | 397 | 431 | 513 | 843 | 1,767 | 1,867 | 2,009 | 2,255 | 2,328 | 2,578 | |
291 | 319 | 331 | 305 | 331 | 387 | 658 | 1,446 | 1,522 | 1,664 | 1,918 | 2,020 | 2,226 | |
Operating Profit | 97 | 85 | 100 | 91 | 99 | 125 | 185 | 321 | 344 | 345 | 337 | 308 | 352 |
OPM % | 25% | 21% | 23% | 23% | 23% | 24% | 22% | 18% | 18% | 17% | 15% | 13% | 14% |
16 | 19 | 28 | 32 | 32 | 35 | 28 | -33 | -123 | 10 | -5 | -0 | 23 | |
Interest | 0 | 0 | 0 | 0 | 1 | 2 | 30 | 140 | 84 | 26 | 16 | 24 | 14 |
Depreciation | 4 | 0 | 8 | 7 | 7 | 9 | 13 | 26 | 25 | 24 | 25 | 24 | 21 |
Profit before tax | 108 | 104 | 120 | 117 | 124 | 150 | 171 | 121 | 112 | 306 | 291 | 260 | 340 |
Tax % | 8% | 5% | 7% | 10% | 10% | 9% | -0% | -17% | -6% | -1% | -7% | -3% | |
99 | 98 | 111 | 105 | 111 | 137 | 171 | 142 | 119 | 309 | 310 | 267 | 325 | |
EPS in Rs | 24.85 | 24.69 | 27.88 | 26.43 | 27.89 | 34.27 | 29.33 | 24.58 | 18.66 | 48.54 | 48.78 | 41.94 | 51.12 |
Dividend Payout % | 24% | 24% | 22% | 25% | 23% | 23% | 17% | 20% | 27% | 10% | 10% | 12% |
Compounded Sales Growth | |
---|---|
10 Years: | 19% |
5 Years: | 23% |
3 Years: | 8% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | 4% |
TTM: | 13% |
Stock Price CAGR | |
---|---|
10 Years: | 5% |
5 Years: | 6% |
3 Years: | 4% |
1 Year: | 14% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 6% |
3 Years: | 6% |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 39 | 39 | 39 | 39 | 39 | 39 | 58 | 58 | 64 | 64 | 64 | 64 | 64 |
Reserves | 217 | 286 | 367 | 439 | 518 | 652 | 3,329 | 3,403 | 4,504 | 4,780 | 5,059 | 5,294 | 5,431 |
0 | 0 | 0 | 0 | 25 | 25 | 1,569 | 1,519 | 550 | 387 | 297 | 329 | 154 | |
93 | 99 | 102 | 89 | 100 | 112 | 503 | 610 | 548 | 461 | 413 | 462 | 359 | |
Total Liabilities | 349 | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,008 |
94 | 95 | 84 | 82 | 103 | 104 | 4,567 | 4,674 | 4,667 | 4,710 | 4,732 | 4,708 | 4,703 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 4 | 4 | 12 | 13 | 10 | 17 |
Investments | 0 | 5 | 0 | 94 | 30 | 148 | 46 | 110 | 0 | 27 | 70 | 78 | 367 |
255 | 324 | 423 | 391 | 550 | 577 | 835 | 802 | 995 | 943 | 1,018 | 1,354 | 921 | |
Total Assets | 349 | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,008 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
69 | 91 | 69 | 90 | 77 | 69 | 149 | 259 | 287 | 237 | 92 | 246 | |
13 | 13 | 29 | -28 | -72 | -59 | -4,092 | -17 | -10 | -59 | -85 | -19 | |
-23 | -27 | -27 | -58 | -6 | -2 | 4,052 | -260 | -216 | -234 | -138 | -26 | |
Net Cash Flow | 59 | 77 | 71 | 4 | -1 | 8 | 109 | -18 | 60 | -56 | -132 | 201 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 1 | 2 | 1 | 3 | 3 | 6 | 42 | 24 | 18 | 26 | 34 | 44 |
Inventory Days | 120 | 108 | 76 | 73 | 127 | 113 | 393 | 168 | 158 | 135 | 146 | 150 |
Days Payable | 136 | 191 | 146 | 191 | 264 | 254 | 662 | 289 | 189 | 136 | 100 | 116 |
Cash Conversion Cycle | -14 | -82 | -69 | -116 | -134 | -135 | -227 | -97 | -13 | 25 | 80 | 78 |
Working Capital Days | -32 | -48 | -37 | -38 | -36 | -8 | 4 | -3 | 12 | 31 | 65 | 71 |
ROCE % | 48% | 35% | 32% | 26% | 23% | 22% | 7% | 6% | 6% | 6% | 6% | 5% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
20h - Disclosure of insider trading by designated person.
-
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
2d - Disclosure of insider trading by director.
- Closure of Trading Window 25 Mar
-
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
24 Mar - Disclosure of insider trading by CFO Umesh Parikh.
-
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
20 Mar - Disclosure of insider trading by designated person.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Oct 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Feb 2017TranscriptNotesPPT
-
Nov 2016Transcript PPT
-
Jul 2016TranscriptPPT
-
Jun 2016TranscriptNotesPPT
Business Segments:[1]
Zydus Wellness operates primarily in the consumer wellness sector. Its key segments include:
a)Food & Nutrition: Notable brands and products such as Glucon-D, Complan, and Sugar-Free.
b) Personal Care: This segment covers products like Everyuth, Scrubs Peel-off masks, and Nycil Prickly Heat Powder.